BACKGROUND: Lymphedema is a poorly understood side effect of gynecologic cancer treatment. This study was designed to determine the prevalence of lower limb lymphedema (LLL) in a sample of ovarian cancer survivors via 3 different diagnostic methods and to assess the effect of a randomized exercise intervention. METHODS: Physically inactive ovarian cancer survivors (n 5 95) were enrolled in a 6-month randomized trial of exercise (primarily brisk walking) versus attention control. LLL was measured at baseline and 6-month visits via a self-report questionnaire, optoelectronic perometry, and an evaluation by a certified lymphedema specialist. RESULTS: LLL prevalence ranged from 21% to 38% according to the diagnostic method, and there was substantial agreement between the self-report questionnaire and the lymphedema specialist evaluation (j 5 0.61). There was no agreement between the evaluation with optoelectronic perometry and the specialist evaluation. With LLL defined by any method, the baseline prevalence was 38% in both groups. At 6 months, both groups experienced a decreased LLL prevalence: 28% in the exercise group and 35% in the control group. There was no difference in the change in lymphedema prevalence between the 2 groups (P 5 .64). Body mass index was a significant predictor of LLL. CONCLUSIONS: With a potential prevalence of LLL as high as 40%, further evaluation of diagnostic methods is required to better characterize this side effect of ovarian cancer treatment. No adverse effect of exercise on LLL was found. Further research is strongly needed to evaluate predictors of LLL and the effects of exercise on LLL in order to develop effective physical activity recommendations for women with ovarian cancer.
INTRODUCTION
Ovarian cancer represents a significant number of the gynecological cancers diagnosed in the United States: it accounts for more than 20,000 cases per year. 1 It is the fifth most frequent cause of cancer death in women after lung, breast, colorectal, and pancreatic cancer. 2 Because it is often asymptomatic until advanced stages, patients frequently present late in the course of the disease, and this makes it difficult to treat. The current standard treatment for ovarian cancer is to optimally remove the tumor surgically and follow up with adjuvant chemotherapy. 3 This treatment approach results in a complete clinical response to therapy in 70% to 80% of patients with advanced-stage disease. 3 Despite the often seen clinical response to treatment, the disease will recur in 60% to 85% of patients diagnosed with advanced disease. 1 Although no proven curative therapy exists for this group of patients, a growing number of new chemotherapeutic agents for recurrent advanced ovarian cancer have been successful at stabilizing the disease and increasing the length of survival of women with recurrent ovarian cancer. 3 In turn, the goals of treatment for women with ovarian cancer are to maximize survival and disease-free intervals and to improve their quality of life.
Each year, thousands of ovarian cancer patients and survivors will develop and endure side effects of their cancer, such as sexual dysfunction, fatigue, and memory loss, which negatively affect their quality of life. 4 One such side effect, lower limb lymphedema (LLL), is a debilitating chronic condition that causes localized swelling in the abdomen and/or legs and feet when lymph vessels become blocked; it can occur after surgery and treatment for various cancers. 5 Because the surgical treatment of ovarian cancer often involves removal of the lymph beds in the pelvic sidewalls and para-aortic area, the risk of LLL is high. 6, 7 However, few women diagnosed with ovarian cancer know that they are at risk for LLL, and few gynecological oncologists discuss this potential side effect with patients when they are reviewing the treatment for their cancer. 8, 9 To date, the majority of research on cancer-related lymphedema has occurred primarily in patients treated for breast cancer, who in some cases develop upper limb lymphedema. [10] [11] [12] [13] Of the studies examining LLL, most have focused on gynecologic cancer generally, with only small samples of ovarian cancer patients included in each study, if any. 9, [14] [15] [16] Among the few studies with samples of ovarian cancer survivors, all have used retrospective chart reviews, and they have reported a prevalence of LLL between 7% and 38%. 8, 9 These studies have noted that adjuvant radiation therapy, obesity, and the degree of lymph node dissection are potential risk factors for the development of LLL. 8, 9, 16 No current estimate based on a prospective method using objective and valid measures exists for the prevalence of LLL. The current gold standard for measuring lymphedema is an evaluation by a trained lymphedema specialist, although recently diagnosis via optoelectronic perometry has become common. 17 Self-report questionnaires have been developed to assess upper limb lymphedema in breast cancer patients 18 ; they provide a quick, low-cost method for collecting information. However, the validity of these questionnaires for assessing LLL has not been assessed in ovarian cancer patients. Similarly, of the few studies examining LLL, none have examined the effects of exercise on lymphedema. Previous studies looking at lymphedema in breast cancer survivors found no adverse effect of exercise. [19] [20] [21] Because of the limited research on the subject, we sought to determine the prevalence of LLL via perometry, a self-report questionnaire, and an evaluation by certified lymphedema specialists in a sample of ovarian cancer survivors. We also sought to assess the validity of the selfreport questionnaire and optoelectronic perometer against the gold-standard lymphedema specialist evaluation, evaluate potential predictors of LLL, and measure the effects of a 6-month randomized trial of exercise versus attention control on lymphedema prevalence within the Women's Activity and Lifestyle Study in Connecticut (WALC). 22 
MATERIALS AND METHODS

Study Participants and Recruitment
This study is part of a larger randomized controlled trial (WALC; n 5 144) designed to determine the effect of a moderate-intensity aerobic exercise intervention versus attention control on the quality of life of physically inactive ovarian cancer survivors. 22 The study reported here is limited to women recruited to WALC from Yale-New Haven Hospital (n 5 95) because LLL assessment was limited to this subgroup.
Briefly, at the Yale study site, Connecticut residents diagnosed with ovarian cancer between 2007 and 2013 were identified via the Rapid Case Ascertainment Shared Resource of the Yale Cancer Center, a field arm of the Connecticut Tumor Registry. Certain data used in this study were obtained from the Connecticut Tumor Registry, which is located in the Connecticut Department of Public Health. We assume full responsibility for the analyses and interpretation of these data. After approval by women's physicians, study staff contacted women and, if they were eligible, invited them to participate in the WALC study. The eligibility criteria included being under the age of 75 years, having completed adjuvant treatment at least 1 month before randomization, having been diagnosed within the past 4 years, and having participated in less than 90 minutes of moderate-intensity aerobic exercise per week. Our standard of care for all patients with epithelial ovarian cancer is a combination of surgery and chemotherapy. For those with early-stage disease, the surgery is performed first, and it is followed by carboplatin and paclitaxel chemotherapy for 6 cycles. Pelvic lymphadenectomies and para-aortic lymph node sampling have been routinely performed in the past, although they have not been performed as meticulously recently. For advanced disease, those patients who are viewed by their gynecologic oncologist to be suitable candidates for primary cytoreductive surgery (PCS) usually undergo pelvic lymphadenectomy and para-aortic lymph node sampling if the peritoneal cavity is optimally surgically cytoreduced. They then receive 6 cycles of adjuvant chemotherapy. Patients who are believed not to be good candidates for PCS undergo neoadjuvant chemotherapy first with carboplatin and paclitaxel for 3 to 6 cycles and then PCS and adjuvant chemotherapy. Lymphadenectomies are routinely performed with PCS after neoadjuvant chemotherapy if the peritoneal cavity is optimally surgically reduced.
Further details about the WALC study and the full recruitment process are described elsewhere. 22 All study procedures were approved by the Yale University human investigations committee, the Connecticut Department of Public Health human investigation committee, and 21 Connecticut hospital institutional review boards.
Baseline Measures
At the baseline visit, information on sociodemographic characteristics and cancer treatments was collected via interview-administered questionnaires, with physician verification of treatment. Height and weight were measured with standard procedures, with the women wearing Original Article light clothing without shoes. Measurements were rounded to the nearest 0.5 cm and the nearest 0.1 kg, respectively.
LLL Assessments
Self-report questionnaire
The Norman Lymphedema Questionnaire is a multisection questionnaire created to evaluate lymphedema; it has been validated in breast cancer survivors for upper limb lymphedema. 18 The questionnaire was modified to focus on lower extremity areas for our study similarly to previous studies evaluating LLL. 23 Women completed a series of questions about observed differences in their feet, lower legs (ankle to knee), upper legs (knee to hip), and abdomen after treatment for ovarian cancer.
Optoelectronic perometer
An optoelectronic perometer test measuring leg volume, conducted by a trained lymphedema specialist, was also used to assess LLL. With the participant standing, the perometer (1000M perometer; Juzo, Cuyahoga Falls, Ohio) measures circumference transections every 4 mm along the leg, and the instrument software calculates the volume of the leg. It has been evaluated extensively for validity and reliability, with one recent study finding both high intrarater reliability (interclass correlation, 0.989; 95% confidence interval, 0.98-0.99) and interrater reliability (interclass correlation, 0.993; 95% confidence interval, 0.99-1.01) in comparison with other volumetric assessments for lymphedema. 17, 24 Before the assessment, women removed all clothing and jewelry from the area. The leg volume was measured once for each leg according to the protocol.
Lymphedema specialist assessment
Women were asked a series of questions by the lymphedema specialist, a physical therapist certified by the Lymphology Association of North America, including 1) whether they had any history of swelling in their legs before surgery and any perceived changes in leg swelling after surgery, 2) whether swelling occurred with physical activity, and 3) whether any changes in leg appearance were seen in the morning versus later in the day. The specialist performed palpations to assess each patient for pitting or induration on both legs and compared the legs. In addition, the specialist also conducted a visual assessment of both legs and notably looked for differences at the dorsum of the foot, toes, and ankles.
All 3 measures of LLL were repeated at the patient's 6-month visit. A single specialist performed all of the evaluations at both the baseline and 6 months.
LLL Definitions
Using the self-report questionnaire, our study defined LLL as any self-reported regular difference in limb/abdomen appearance (primarily size but also heaviness, skin texture/coloration, swelling/puffiness, and so forth) in comparison with the other leg/side of the abdomen and/ or the appearance of the limb/abdomen before treatment for ovarian cancer. With the optoelectronic perometer assessment, lymphedema was defined as an interlimb volume discrepancy of 5% or more. This was based on standard definitions set forth by the International Society of Lymphology, which has defined mild lymphedema as a limb volume difference of 5% or more. 25 The lymphedema specialist categorized the participant as either having lymphedema or not having lymphedema at the time of the assessment according to the assessment performed. Using his visual inspection and palpations, the specialist defined no lymphedema as no pitting, no palpable induration, no patient-reported history of swelling (with and without physical activity), no patient-reported appearance changes between the pre-and posttreatment periods, and no visual differences in appearance at the assessment.
Exercise Intervention
The exercise intervention consisted of a 6-month homebased moderate-intensity aerobic exercise program facilitated by weekly telephone calls from an American College of Sports Medicine-certified cancer exercise trainer. Women in the exercise arm were asked to participate in moderate-intensity aerobic exercise, mainly brisk walking, for 150 min/wk. They were asked to record their activity in a daily activity log and to include the type, duration, and intensity (from study-provided heart rate monitors) of their physical activity.
The trainer provided weekly counseling and support via telephone to motivate participants using a 26-chapter book developed for the study (1 chapter per week of intervention). The attention control arm received weekly phone calls from a WALC staff member along with a 26-chapter book containing only information related to ovarian cancer survivorship. One chapter was discussed during each weekly call.
Statistical Analysis
We performed descriptive statistics to describe the characteristics of our study population and the treatment that they received. To assess agreement between the 3 diagnostic methods, simple j statistics were calculated. A simple j statistic was used to measure the level of agreement and the degree of disagreement, with a maximum value of 1 indicating perfect agreement and values greater than 0.61 suggesting substantial agreement. 26, 27 Optoelectronic perometer and self-report questionnaire results were compared with the results of the lymphedema specialist evaluation, which was considered the gold-standard diagnostic method. Analyses of the effect of physical activity on LLL were performed with a repeated measures analysis 28 to evaluate the baseline to 6-month differences. Differences were evaluated between women randomized to exercise or attention control according to the intentionto-treat principle. Finally, generalized estimating equations were used to evaluate the change in the risk of LLL from the baseline to 6 months between the 2 study arms.
28 P values were 2-sided, and P < .05 was used as the threshold for statistical significance. All statistical analyses were conducted with SAS software (version 9.3; SAS, Cary, North Carolina).
RESULTS
All 95 women completed the baseline visit at Smilow Cancer Hospital at Yale-New Haven Hospital (Fig. 1) . There was no statistical difference in any of the demographics (age, race, marital status, educational status, and employment status) or medical characteristics (body mass index [BMI] , smoking status, previous use of birth control pills, time since diagnosis, cancer stage, and treatment received) between the 2 study arms (exercise intervention [n 5 50] and attention control [n 5 45]; Table 1 ). On average, the women were 58 years old (exercise intervention, 58.1 6 8.6 years; attention control, 58.9 6 7.4 years; P 5 .63), non-Hispanic white (exercise intervention, 98.0%; attention control, 93.3%; P 5 .26), and 18 months from their diagnosis (exercise intervention, 19.7 6 10.8 months; attention control, 17.9 6 10.7 months; P 5 .43). In both groups, half of the women had been diagnosed with stage III or IV ovarian cancer (exercise intervention, 50.0%; attention control, 51.1%; P 5 .51). There was no difference in comorbidity prevalence between the 2 study arms for the following comorbidities: arthritis, angina, asthma, depression, diabetes, history of foot swelling, heart attack, congestive heart failure, heart disease, hypertension, hyperlipidemia, hypertriglyceridemia, history of hip fracture, history of hip replacement, history of knee pain, osteoporosis, history of any other fracture, and stroke.
LLL Prevalence and Diagnostic Agreement Between Assessment Methods
All 95 women completed the self-report questionnaire at the baseline, and 22.1% (n 5 21) were classified as having lymphedema. Among the women with self-report-based LLL, 52.4% (n 5 11) reported lymphedema-like symptoms in their feet, 61.9% (n 5 13) reported symptoms in their lower legs, 9.5% (n 5 2) reported symptoms in their upper legs, and 47.6% (n 5 10) reported symptoms in their abdominal area. Nine women (42.8%) reported lymphedema-like symptoms in multiple regions of their lower limbs. Because the LLL substudy of WALC was initiated approximately 1 year after the WALC study began, only 63 women (66.3%) received baseline evaluations with the optoelectronic perometer. Of these 63 women, 26.9% (n 5 17) were diagnosed with LLL. Individuals diagnosed with LLL via the perometer had an average interlimb difference of 6.0% (standard deviation, 1.3%; range, 5%-9%). All the women positive for lymphedema via the perometer were classified as having mild lymphedema (ie, an interlimb difference between 5% and 9%). 25 A total of 62 women (65.3%) had a comprehensive evaluation by the lymphedema specialist at the baseline, and 20.9% of these women (n 5 13) were diagnosed as having lymphedema.
Overall, 37.8% of the women (n 5 36) had an LLL diagnosis by at least 1 of the 3 diagnostic measures, whereas zero study participants had an LLL diagnosis by all 3 methods. Prevalence results are summarized in Table 2 .
Within the group of 62 women who had all 3 assessments, the self-report questionnaire showed substantial agreement (j 5 0.61) with the lymphedema specialist evaluation. 23, 24 Conversely, the optoelectronic perometer showed no agreement (j 5 -0.04) with the specialist evaluation. The perometer also exhibited no agreement with the self-report questionnaire (j 5 0.00; Table 3 ).
Effect of the Exercise Intervention
At the baseline, there was no difference in the prevalence of LLL between the exercise intervention group and the attention control group by any diagnostic method (Table  4) . Both study groups showed a decrease in the prevalence of LLL assessed by any diagnostic method at 6 months versus the baseline prevalence. At 6 months, among the 80 women who completed both baseline and 6-month assessments, the prevalence of LLL with any definition of LLL was 28% in the exercise intervention group versus 33% at the baseline (a 15% reduction), and it was 35% in The data are presented as the number of subjects diagnosed with lymphedema by the listed method; percentages are shown in parentheses. the attention control group versus 38% at the baseline (an 8% reduction). There was no significant difference in the change in LLL prevalence between the 2 study groups over the 6-month study (P 5 .64). We saw no difference between the exercise intervention group and the attention control group in terms of the change in the risk of LLL (P 5 .83) after 6 months of participation in the study. Furthermore, neither the exercise intervention group (odds ratio, 0.80; 95% CI, [0.47, 1.36]; P 5 .41) nor the attention control group (odds ratio, 0.89; 95% CI, [0.42, 1.90]; P 5 .76) had a change in the risk of LLL from the baseline to 6 months. Among women without LLL at the baseline, fewer women in the exercise intervention group developed LLL (4.8% [n 5 2]) in comparison with women in the attention control group (13.5% [n 5 5]), although this result was not statistically significant (P 5 .20).
Predictors of LLL
An exploratory evaluation of predictors of LLL was performed. When we controlled for demographic and treatment factors and used an LLL diagnosis by any method, the BMI was found to be significantly lower in the women who did not have LLL at the baseline (27.8 6 5.8 kg/m 2 ) versus those who did have LLL (31.7 6 7.7 kg/m 2 ; P < .01). No other patient characteristics were found to be significantly different between the 2 groups.
DISCUSSION
We found that the prevalence of LLL in ovarian cancer survivors ranged from 21% to 38%, and it was dependent on the diagnostic method used. Individually, the 3 diagnostic methods evaluated-the self-report questionnaire, the optoelectronic perometer, and the lymphedema specialist evaluation-each indicated a prevalence of LLL of 21% to 27%, but when they were used collectively, the prevalence was 38%. The self-report questionnaire had strong agreement with the gold-standard evaluation by a trained lymphedema specialist, whereas there was no agreement between the optoelectronic perometer and the trained specialist evaluation. Importantly, our results showed no adverse effect of participation in our exercise intervention on LLL.
The prevalence differences observed from using the different diagnostic methods indicate the limitations of each method. Although the self-report questionnaire is easy and quick to administer, it remains a subjective evaluation of LLL that has not been validated before for LLL or in gynecologic cancer survivors. Our findings represent an initial validation for the questionnaire in this population and indicate that it may be a preferable diagnostic method in comparison with the perometer. Importantly, lymphedema is not a constant chronic condition and may fluctuate. 14 As such, the self-report questionnaire may be a very useful tool for determining prevalence because it asks women to recall changes over time in contrast to the crosssectional results produced by the perometer.
Unlike the questionnaire, the perometer provides an objective measurement of limb volume on which to base an LLL diagnosis. It can detect very small differences in limb volume that are symptomatic of lymphedema, which may be overlooked by the lymphedema specialist. This may be the reason that, with the 3 methods, the prevalence of LLL (27%) was highest when the evaluation was made via the perometer alone. However, the perometer is severely limited by the fact that it is unable to diagnose lymphedema in women who are experiencing LLL in both legs. Because surgical treatment for gynecologic cancer involves bilateral lymph node dissection, LLL is often experienced bilaterally.
14 For these women who would be experiencing swelling in both legs, the perometer would fail to identify a meaningful interlimb volume difference needed to diagnose LLL. One potential solution is to collect pretreatment perometer measures of each limb and compare later perometer results with pretreatment results rather than evaluating interlimb differences after treatment. However, this does not amend the fact that the perometer would fail to identify lymphedema that may be occurring in a woman's abdomen because it is limited to measuring limb volume. This may be why the optoelectronic perometer had such a low agreement with both of the other diagnostic methods.
The lymphedema specialist evaluation remains the gold standard because it takes both subjective factors, such as a patient-reported history of swelling and changes in the range of motion, and objective factors, such as induration and pitting, into consideration for the diagnosis of LLL. However, the evaluation is a time-intensive process. The reasonably high agreement of the self-report questionnaire with the lymphedema specialist indicates that with further validation, the self-report questionnaire could be a useful tool in preliminarily diagnosing LLL.
Previous literature on LLL has reported a prevalence of LLL of 7% to 38% in women after treatment for gynecologic cancer. 8, 9 All of these studies evaluated LLL through retrospective chart reviews of clinically diagnosed lymphedema, and this is a limitation of their findings. Our study is the first to look at LLL prevalence exclusively in ovarian survivors, and it used multiple diagnostic methods to assess LLL as women were experiencing symptoms; this likely produced a better measure of LLL prevalence. Collectively, our findings, combined with previous research, indicate that a relatively high proportion of ovarian cancer survivors may be experiencing LLL. Notably, previous research has also shown a general lack of knowledge among patients about lymphedema related to gynecologic cancer treatment. 8, 14 Our study found that only 50% of our study population had been informed about the condition previously. This represents a deficiency in the current standard of care, particularly if the prevalence of LLL could be as high as 40%.
Interestingly, in our preliminary analysis of potential risk factors for LLL, we found that those women with LLL at the baseline had significantly higher BMIs than those who did not have LLL. This result is similar to the results of several previous studies that found higher BMIs in breast cancer survivors with upper extremity lymphedema versus breast cancer survivors without lymphedema. 29, 30 One study found that breast cancer survivors whose BMI was greater than 30 kg/m 2 were 3.6 times more likely to develop lymphedema than those with a BMI less than 30 kg/m 2 . 30 The only other study looking at lymphedema risk factors in gynecologic survivors did not find any significant association between LLL and BMI in ovarian cancer survivors, although an association was found with uterine cancer survivors. 8 Our results, combined with previous literature, indicate a need for further research related to risk factors for LLL in this population of survivors.
Our study is the first to evaluate the effects of an exercise intervention on LLL in this population. Importantly, we did not find any adverse effect of exercise on LLL in this patient population. Among women who did not have LLL at the baseline, there was no statistical difference in LLL prevalence at 6 months between those women who participated in the exercise intervention and those in the attention control group. These results are consistent with breast cancer literature showing that weight-training and exercise interventions do not exacerbate or remit upper extremity lymphedema. [19] [20] [21] Future studies need to evaluate the effects of exercise on LLL further in a larger sample of gynecologic cancer survivors to develop physical activity guidelines for these survivors.
The limitations of our study need to be considered when our results are being interpreted. Despite our sample being significantly larger than those of most other studies evaluating LLL in ovarian cancer survivors, its small size limited our ability to detect significant differences between our exercise intervention and attention control study arms and to evaluate possible predictors of LLL fully. In addition, we had a significant number of women who did not receive all 3 lymphedema evaluations at their 6-month follow-up visit, and this limited our ability to analyze the effects of the intervention.
In summary, among ovarian cancer survivors, the prevalence of LLL ranged from 21% to 38%. The fairly high diagnostic agreement between the self-report questionnaire and the lymphedema specialist evaluation indicates the potential usefulness of the self-report questionnaire in diagnosing LLL. Similarly the low agreement of both of those methods with the optoelectronic perometer illustrates the major limitation of the perometer: it cannot diagnose LLL when it is occurring in both legs simultaneously or in the abdomen. Our findings indicate that diagnosis via multiple methods may be the most accurate way of diagnosing LLL because this may be the best way to detect lymphedema symptoms in the entire leg from abdomen to feet, even in the mildest forms and even when symptoms may be remitting. Our study found no adverse effect of participation in our home-based exercise intervention on LLL, and these results are consistent with previous breast cancer research. Despite the fairly high prevalence of LLL that we found, only approximately half of the women in our study had heard of lymphedema before participation, and this indicates a large information gap. The lack of significant literature on the subject of LLL in ovarian cancer survivors and with respect to gynecologic cancers in general indicates a strong need for further research, particularly if the prevalence of LLL could be as high as 40% among women treated for these cancers.
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